Immatics N.V. Ordinary Shares (IMTX)
- Headquarters
- United States
- Employees
- 407
- Market Cap
- $1.3B
About Immatics N.V. Ordinary Shares
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
SentiSense also tracks daily options readings for Immatics N.V. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Immatics N.V. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.